Tag Archive for: oncology

STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024

/in

STC-15 is the first METTL3 inhibitor to enter clinical development Clinical data will include safety, pharmacology, target modulation, and clinical activity 24 May 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that it will be presenting interim clinical data on its […]

Read more

NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb

/in

Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selection London, UK, 22 May 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round. The additional investment […]

Read more

Publication in Nature Immunology outlining the contribution of B cells to anticancer immunosurveillance highlights Alchemab’s capabilities and potential to develop new cancer therapies

/in

Cambridge, UK, 14 May 2024 – Alchemab Therapeutics (Alchemab), an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announces the publication of a peer reviewed article titled “Predictability of B cell clonal persistence and immunosurveillance in breast cancer” in the journal Nature Immunology. The senior author Rachael Bashford-Rogers is a co-founder of […]

Read more

Poolbeg Pharma – Results for the year ended 31 December 2023

/in

Significant pipeline advancements Strategic expansion into cancer immunotherapy-induced CRS unlocking a market opportunity exceeding US$10Bn Key senior management hires 30 April 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces its audited results for the […]

Read more

Outrun Therapeutics launches with a $10m seed financing from M Ventures and MP Healthcare Venture Management to develop a protein stabilisation pipeline

/in

Proprietary E3 ligase platform to enable protein stabilisation “at source”, thereby restoring the body’s sophisticated natural disease suppression processes Platform scales the assessment of E3 ligase targets while addressing the historic challenges of drugging these targets Pipeline of first-in-class, small molecule, E3 ligase inhibitors to stabilise proteins and treat disease in several therapeutic areas, including […]

Read more